When IL-17 Blockade Backfires: Retropharyngeal Granuloma and Petrous Bone Osteonecrosis in a Patient with Psoriasis
Keywords:
Ixekizumab, Interleukin-17, Paradoxical reaction, Psoriasis, Granulomatous diseaseReferences
Dapavo P, Siliquini N, Mastorino L, et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatolog Treat. 2022;33(4):2352-2357. doi:10.1080/09546634.2021.1961998
Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature. Reacciones paradójicas de los tratamientos biológicos utilizados en psoriasis: revisión de la literatura. Actas Dermosifiliogr (Engl Ed). 2018;109(9):791-800. doi:10.1016/j.ad.2018.04.003
Kirby C, Herlihy D, Clarke L, Mullan R. Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis. BMJ Case Rep. 2021;14(2):e240615. Published 2021 Feb 22. doi:10.1136/bcr-2020-240615
Hauer L, Moztarzadeh O, Baghalipour N, Gencur J. Secukinumab Causing Medication-Related Osteonecrosis of the Jaw, in a Patient Diagnosed with Psoriasis and Rheumatoid Arthritis. Psoriasis (Auckl). 2024;14:115-120. Published 2024 Sep 23. doi:10.2147/PTT.S490982
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038/clpt.1981.154
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Luca Cangialosi, Umberto Santaniello, Michela Ortoncelli, Pietro Quaglino, Simone Ribero

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

